Press release - March 13th, 2014

Cerbomed GmbH at the 30th International Congress of Clinical Neurophysiology

ERLANGEN/BERLIN, 13.03.2014 – From March 19th until 23rd 2014 the medical device company cerbomed GmbH from Erlangen, Germany, will present the transcutaneous Vagus Nerve Stimulation (t-VNS) at the 30th International Congress of Clinical Neurophysiology.   
Please save March 21st and use the chance to get additional information about t-VNS at the Lunch Symposium “Transcutaneous Vagus Nerve Stimulation (t-VNS). Treatment option in epilepsy and pain.” from 12:15 to 13:45 p.m.

About t-VNS
The t-VNS offers a therapy option for patients suffering from epilepsies, depression or pain.
This therapy uses a branch of the vagus nerve that is located closely under the skin in areas of the outer ear and therefore can be stimulated through the skin (transcutaneously) with electrical impulses.
The t-VNS therapy is carried out autonomously by the patients and is easy to integrate into the daily routine. The advantages of t-VNS: No surgery, no hospitalization, minor side effects.

About cerbomed
Cerbomed GmbH is an innovative medical device company located in Erlangen, Germany, that focuses on neuromodulation. The company, founded in 2005, focuses on transcutaneous Vagus Nerve Stimulation (t-VNS), which may offer an attractive therapy option for patients with hard-to-treat neurological and psychiatric illnesses.
The transcutaneous Vagus Nerve Stimulation received the European clearance (CE mark) for the treatment of epilepsies, depression and pain. Currently two clinical studies are carried out regarding the effectiveness of t-VNS in patients with drug-resistant epilepsy and chronic migraine.
In September 2012 cerbomed entered into a strategic partnership with Cyberonics, Inc., the global market leader in vagus nerve stimulation.
The therapy device NEMOS is available for treating epilepsies in Germany, Austria, Switzerland and Italy.

pdf Download Article


Please note: NEMOS® is not cleared or approved for use in the U.S.